–2021, the change in cost of sales and services was in line with the changes in revenue. However, the increased rate of cost will be higher than the increased rate of revenue when comparing between Q1
on the dept cost structure analysis for the investment in the biogas power plant project of Aukkrarawat that the Board of Directors has considered additional facts and the study of the change in cost
on the dept cost structure analysis for the investment in the biogas power plant project of Aukkrarawat that the Board of Directors has considered additional facts and the study of the change in cost
) Cost of sales Consolidated financial statements Change Increase/(Decrease) For Three Months Period Ended 31 March 2018 2019 THB mm % THB mm % THB mm % Raw material and packaging 78.40 77.62 33.96 62.84
December 31 2019 2018 Change MB % MB % MB % Cost of sales 157.39 41.87 125.04 39.37 32.35 2.50 Selling expenses 106.75 28.40 101.32 31.90 5.43 3.50 Administrative expenses 49.98 13.30 50.26 15.83 (0.28
bonus forgone by an executive into other income of Baht 2.25 million. For the Year Ended December 31 2019 2018 Change MB % MB % MB % Cost of sales 157.39 41.87 125.04 39.37 32.35 2.50 Selling expenses
bonus forgone by an executive into other income of Baht 2.25 million. For the Year Ended December 31 2019 2018 Change MB % MB % MB % Cost of sales 157.39 41.87 125.04 39.37 32.35 2.50 Selling expenses
Floor, Silom Road, Suriyawong, Bangrak, Bangkok 10500, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th 3-Month Period Ending March 31st 2020 2019 Change MB % MB % MB % Cost of Sales 35.76
operating expenses in Q1–2021 increased from Q1–2020 and decreased from Q4–2020 at a similar rate with an increase or decrease in revenue each quarter, mainly due to the change rate in the cost that increases
operating expenses in Q1–2021 increased from Q1–2020 and decreased from Q4–2020 at a similar rate with an increase or decrease in revenue each quarter, mainly due to the change rate in the cost that increases